Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Trinity Health Ann Arbor at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Trinity Health Ann Arbor brings 5 presentations to SITC 2026 in Phoenix. Its program centres on large population studies of cancer survivors' risk of a second, new cancer in the immunotherapy era. It also compares survival in multiple myeloma after CAR T-cell therapy versus teclistamab, both aimed at BCMA, using real-world data.

Organization	SITC 2026 Attendance
TH Trinity Health Ann Arbor Ann Arbor, MI
	Poster Fri Nov 6 12:15–1:45pm 5:30–7pm Racial Disparities in Second Primary Hematologic Malignancy Risk During the Chronological Immunotherapy Era Among Renal Cell Carcinoma Survivors: A SEER Population-Based Analysis Exhibition Halls 4-6 · Poster 407 Clinical Poster Fri Nov 6 12:15–1:45pm 5:30–7pm Second Primary Malignancy Risk in the Immunotherapy Era Among Urothelial Carcinoma Survivors: A SEER Population-Based Analysis Exhibition Halls 4-6 · Poster 455 Clinical Poster Fri Nov 6 12:15–1:45pm 5:30–7pm Survival Trends and Clinical Outcomes in Multiple Myeloma Following BCMA-Directed Immunotherapy: A Propensity Score–Matched Real-World Comparison of CAR-T Cell Therapy versus Teclistamab Exhibition Halls 4-6 · Poster 613 Cell therapy · Clinical Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Second Primary Hematologic Malignancies in Melanoma Survivors Before and After the Introduction of Immune Checkpoint Inhibitors: A Population-Based SEER Analysis Exhibition Halls 4-6 · Poster 454 Clinical Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Second Primary Malignancy Risk Across Treatment Eras in Head and Neck Squamous Cell Carcinoma Survivors: A SEER Population-Based Analysis Exhibition Halls 4-6 · Poster 408 Clinical

Organization

SITC 2026 Attendance

Trinity Health Ann Arbor

Ann Arbor, MI

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

Racial Disparities in Second Primary Hematologic Malignancy Risk During the Chronological Immunotherapy Era Among Renal Cell Carcinoma Survivors: A SEER Population-Based Analysis

Exhibition Halls 4-6 · Poster 407

Clinical

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

Second Primary Malignancy Risk in the Immunotherapy Era Among Urothelial Carcinoma Survivors: A SEER Population-Based Analysis